Paul L. Berns, President and CEO at Anacor Pharmaceuticals, Inc. (ANAC), sold 20,000 shares at $117.04 ($2.3M) on 2015-12-11, disclosed to the SEC on 2015-12-15.
Scheduled sale ($2.3M) by President and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $115.52 | 590 | $68K | 2.9% |
| 2 | $117.04 | 10,732 | $1.3M | 53.6% |
| 3 | $117.60 | 8,178 | $962K | 41.0% |
| 4 | $118.59 | 500 | $59K | 2.5% |
| Total | $117.26 avg | 20,000 | $2.3M | 100% |
| Filing → |
| NMRA | SELL | 2026-02-19 | $34K | — | Filing → |
| NMRA | SELL | 2025-02-20 | $23K | — | Filing → |
| MTSR | BUY | 2025-02-03 | $14.2M | — | Filing → |